Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

Lucienne Ronco1, Diego Cadavid1, Jayashree Chadrangankar1 Aaron Chang3, Michelle Melion1, Alan Robertson1, Alejandro Rojas1, Ning Shen1, Rabil Tawil1, Stephen Tapscott1, Leo Wang4, Owen Wallace1
1Fulcrum Therapeutics, 26 Longfellow Street, Cambridge, Massachusetts, USA
2Wellstone Neuro-Muscular Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
3Human Biology Division, Fred Hutchinson Research Center, Seattle, Washington, USA
4Department of Neurology, University of Washington, Seattle, Washington, USA

Abstract

Both genetic types of facioscapulohumeral muscular dystrophy (FSHD) are caused by the aberrant expression of the homeobox transcription factor DUX4. Ectopic DUX4 expression in skeletal muscle is the root cause of FSHD. Ablation of DUX4 expression in maturing myoblasts activates a complex transcriptional program that leads to myocyte death and replacement of muscle with fat. DUX4 expression results in profound transcriptional dysregulation and a characteristic DUX4-regulated signature has been described by many laboratories. Clinical evaluation of the p38-α inhibitor losmapimod is ongoing including the assessment of drug exposure, target engagement and inhibition of the DUX4 transcriptional program in muscle biopsies. Reliable detection of DUX4 protein and mRNA in affected FSHD skeletal muscle biopsies is challenging as the levels are very low and likely short lived. Conversely, levels of DUX4-regulated transcripts are much higher and longer lasting. Here we used RNA-Seq profiling of repeated FSHD skeletal muscle biopsies to design a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD trials.

Objectives:

• Identify DUX4-regulated gene transcripts to measure DUX4 activity in skeletal muscle needle biopsy in preparation for ongoing FSHD clinical trials with losmapimod (Ph1 study FIS 001-2018, placebo-controlled ReDUX4 phase 2b study FIS 003-2019 and phase 2 open label study FIS 001-2019).
• Assess the longitudinal variability under natural history conditions of DUX4-regulated gene transcripts in MRI-affected skeletal muscle needle biopsy samples from FSHD patients with moderate disability (Picsi score 2-4).
• Identify a subset of these transcripts that exhibit higher expression and lower variability in repeated biopsies.

1. Background

(A) Schematic of the loss in gene repression caused by contraction of DUX4 repeats that leads to DUX4 expression
(B) Schematic describing the downstream transcriptional consequences in the muscle of FSHD subjects.

2. MRI guided skeletal muscle biopsies collected and analyzed for DUX4 transcriptional signature

(A) Schematics of the design of the Wellstone natural history study in FSHD subjects (Wang et al., 2018)
(B) Schematic of the design of Fulcrum Therapeutics natural history preparatory study SRA-002-2018
(C) Representative images of Magnetic Resonance Imaging. Presence of short tau inversion recovery (STIR) positive signal with intermediate degree of fat replacement in at least one leg muscle was required for eligibility.

3. Analytical Approach

A comparative differential analysis of transcriptomes from control and affected FSHD muscle biopsies was conducted to identify a subset of DUX4-regulated gene transcripts that could serve as the proof of concept efficacy biomarker of DUX4 activity

4. Results: A stable subset of DUX4-regulated gene transcripts can be detected in skeletal muscle biopsies taken 1 year apart

A. At visit 1, 47 transcripts fulfilled selection criteria
B. 35 transcripts are stably detected after one year

(A) Fulcrum SRA 002-2018

(C) The RNAseq transcript heatmap displays Gene Fragments Per Kilobase of transcript per Million (FPKM) mapped reads for all genes in the gene subset. FPKM value is log2(FPKM). Control and FSHD samples (visits 1 and 2) are included in the data set.

(D) Bioplot of DUX4-regulated and differentially expressed transcripts identified in FSHD skeletal muscle compared to healthy biopsies. Transcripts are sorted by mean abundance in expression across all groups. Abundance is calculated as the log2 of FPKM.

5. A subset of genes was confirmed to be directly regulated by DUX4

(C) FSHD myoblasts were differentiated in culture for 5 days and simultaneously treated with losmapimod, DMSO, scrambled or DUX4 antisense (ASO) oligonucleotide. GPCR reactions for DUX4, MBDS2, and Gene C were carried out.

6. Conclusion

This study identified DUX4 regulated gene transcripts that are stably expressed for at least one year in affected muscle biopsies from FSHD subjects. An initial subset of DUX4 regulated gene transcripts to use as biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD trials has been identified. The analysis of Fulcrum study SRA-002-2018 is still ongoing.

References

(1) Wang et al., 2018
(2) Jagannathan et al., 2016
(3) Rojas et al., 2019; P38α Regulates Expression of DUX4 in Facioscapulohumeral Muscular Dystrophy